NEW YORK (GenomeWeb News) – Ligon Discovery, a protein microarray developer based in Cambridge, Mass., has reeled in $1 million in financing from IncTank Ventures, Ligon Discovery Co-founder Patrick Kleyn confirmed today.
The firm plans to use the venture funding to screen more than 100 proteins that could be used for drugs.
Ligon's small-molecule microarrays (SMMs) technology platform was developed by and licensed from Harvard University and Broad Institute.
SMMs use surface chemistry technology to attach unmodified chemical collections to a solid surface, enabling massively-parallel screening against protein targets of any function, according to the firm's website.
The technology enables researchers to screen entire protein families, molecular pathways, and genome-wide targets in parallel to identify small molecules with optimal characteristics for drug development.
The company also confirmed that IncTank General Partner Christian Bailey has joined Ligon's board of directors.